76081-97-5

Usage

Uses

Used in Pharmacology:
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 4-pyren-1-ylbutanoate is used as a potential therapeutic agent for various medical conditions due to its complex structure and the presence of multiple functional groups that may interact with biological targets.
Used in Biochemistry:
In the field of biochemistry, [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 4-pyren-1-ylbutanoate is used as a research tool to study the interactions between complex molecules and biological systems, potentially leading to a better understanding of molecular mechanisms and the development of new drugs.
Used in Materials Science:
Within materials science, [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 4-pyren-1-ylbutanoate may be utilized in the development of novel materials with specific properties, such as improved drug delivery systems or advanced materials with unique optical, electronic, or mechanical characteristics.
Used in Drug Delivery Systems:
In the development of drug delivery systems, [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 4-pyren-1-ylbutanoate is used as a component in the design of targeted drug delivery vehicles, potentially enhancing the efficacy and specificity of therapeutic agents.
Used in Chemical Synthesis:
In the field of chemical synthesis, [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 4-pyren-1-ylbutanoate serves as a starting material or intermediate in the synthesis of other complex molecules with potential applications in various industries.

InChI:InChI=1/C47H60O2/c1-30(2)9-6-10-31(3)40-23-24-41-39-22-20-36-29-37(25-27-46(36,4)42(39)26-28-47(40,41)5)49-43(48)14-8-11-32-15-16-35-18-17-33-12-7-13-34-19-21-38(32)45(35)44(33)34/h7,12-13,15-21,30-31,37,39-42H,6,8-11,14,22-29H2,1-5H3/t31-,37+,39+,40-,41+,42+,46+,47-/m1/s1

Upstream product

• 57-88-5 cholesterol 
• 63549-37-1 4-(pyren-1-yl)butyryl chloride 

Relevant academic research and scientific papers

Synthesis, Structure, and Excimer Formation of Aromatic Cholesteric Liquid Crystals

Cholesteryl ο-arylalkanoates having phenyl, 1-naphthyl, and 1-pyrenyl groups as aromatic groups were synthesized, and some of those were found to form the cholesteric liquid crystal (CLC) phase.The pitch and the screw sense of the helix were determined from the selective reflection wavelength and the circular dichroism.The pitch was around 800 nm for cholesteryl 5-(1-naphthyl)pentanoate and about 970 nm for cholesteryl 3-(1-naphthyl)propionate.The helix sense was left-handed for all cholesteryl esters which form the CLC phase.The orientation of naphthyl groups within each quasi-nematic layer was qualitatively discussed from the sign of cirular dichroism at the 1La absorption band.The short axis of the 1-naphthyl group was parallel to the optical or the molecular axis of the quasi-nematic layer in the CLC of cholesteryl 1-naphthylpropionate and -pentanoate, whereas the short axis of 2-naphthyl group was perpendicular to the optical axis of the CLC of cholesteryl 2-naphthylpropionate.The orientation of the excimer transition moment was investigated by circularly polarized fluorescence spectroscopy.The transition moments for all chromophoric CLC's were found to be nearly perpendicular to the optical axis.From these spectroscopic data, an intralayer excimer configuration for 1- and 2-naphthyl groups was proposed.In the mixture of cholesteryl 3-(1-pyrenyl)propionate (60 molpercent) and 3-phenylpropionate (40 mol percent), the excimer formation was more efficient in the CLC phase than in the crystalline phase.